Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara) announced that the Company decided the following changes of Members of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers at its Board of Directors Meeting held today.

The appointments for candidates of Members of the Board of Directors and Audit & Supervisory Board Members will be resolved at the 73rd Annual Shareholders Meeting Scheduled for the mid of June 2021. The changes and appointments of Members of the Board of Directors, Standing Audit & Supervisory Board Members and Corporate Officers will be officially decided at the Board of Directors Meeting to be held on the same day of the Annual Shareholders Meeting.

1. Changes of Members of the Board of Directors (as of mid of June 2021)

Incumbent Members of the Board of Directors will be re-appointed.

1. New candidate of Members of the Board of Directors

Kiyoaki Idemitsu Corporate Executive Officer, Executive Director, Clinical Development

1-2 Resigning Members of the Board of Directors

Hiroshi Awata Vice President, Executive Officer, Tokyo Branch Head

After resigning, he will be appointed as a senior partner.

Jun Kurihara Outside Members of the Board of Director

2. Audit & Supervisory Board Members (as of mid of June 2021)

2-1 New candidate of Outside Audit & Supervisory Board Member (current post in the bracket)

Hironobu Tanisaka (full-time)(Currently: Director, Business Audit Department)

2-2 Resigning outside Audit & Supervisory Board Members (voluntarily)

Shinji Fujiyoshi (full-time)(Currently: Audit & Supervisory Board Member)

After resigning, he will be appointed as a part-time adviser.

3. Changes of Corporate Officers (as of mid of June 2021)

Except for the following candidates of Corporate Officers, incumbent Corporate Officers will be re-appointed.

3-1 New candidates of Corporate Officer

Masaki Ito Director, Corporate Planning Department

3-2 Resigning Corporate Officers

Katsunori Morio Corporate Officer, Division Director, Sales Division, Metropolitan Region

After resigning, he will be appointed as a full-time adviser.

Takuya Seko Corporate Officer, Senior Director, Quality Assurance Management

After resigning, he will be appointed as an Officer.

The followings are the appointments of Members of the Board of Directors, Audit & Supervisory Board Members, and Corporate Officers (as of mid of June 2021).

Candidates of Members of the Board of Directors and Audit & Supervisory Board Members for subject to approval at the 73rd Annual Shareholders Meeting

Members of the Board of Directors?

Gyo Sagara President, Representative Director

Isao Ono Executive Officer, Director, Corporate Research<

Toshihiro Tsujinaka Executive Director, Corporate Strategy & Planning

Toichi Takino Executive Director, Discovery & Research

Kiyoaki Idemitsu Executive Director, Clinical Development

Masao Nomura Outside Director

Akiko Okuno Outside Director

Shusaku Nagae Outside Director

Audit & Supervisory Board Members

Katsuyoshi Nishimura Audit & Supervisory Board Member (full-time)

Hironobu Tanisaka Audit & Supervisory Board Member (full-time)

Yasuo Hishiyama Outside Audit & Supervisory Board Member

Akiko Tanabe Outside Audit & Supervisory Board Member Corporate Officers?

Hiroshi Ichikawa Corporate Senior Executive Officer, Executive Director, Sales and Marketing

Yukio Tani Corporate Executive Officer, Head of Corporate Communications

Shozo Matsuoka Corporate Executive Officer, Executive Director, Corporate Regulatory Compliance, Safety and Quality Assurance

Katsuji Teranishi Corporate Officer, Division Director, Sales Division, Western Japan Region

Hiromu Habashita Corporate Officer, Deputy Executive Director, Discovery & Research

Shinji Takai Corporate Officer, Head of Medical Affairs / Head of Data Strateg

Keiji Masui Corporate Officer, Division Director, Sales Division, Eastern Japan Region

Masaki Ito Corporate Officer, Director, Corporate Planning Department

Contact:

Ono Pharmaceutical Co., Ltd.

Corporate Communications

E: public_relations@ono.co.jp

(C) 2021 Electronic News Publishing, source ENP Newswire